Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
July 13, 2013 --Kinex Pharma of New York State extended its relationship with South Korea’s Hanmi Pharma by gaining the right to lead Hanmi’s Orascovery program development in China; Tianjin Weikai obtained exclusive China rights to manufacture and distribute TissueFlex®, a microbioreactor, from the UK’s Zyoxel; SciClone will collaborate with Soligenix of New Jersey to develop a personal medicine treatment for oral mucositis; Luqa Pharma partnered with BMG Pharma S.r.l. of Italy to bring BMG’s dermatology and oral care products to China; DelMar Pharma reported that its partner, Guangxi Wuzhou Pharma, received government support for its collaboration with DelMar; GlaxoSmithKline’s China scandals have cast a pall over the entire company’s reputation, and its problems may affect the China operations of other multinationals as well; GSK executives in China have reportedly confessed to bribing government officials, hospitals and doctors, a scheme that has been in place for “years;” GSK’s sales force in Chengdu alledgedly hatched a scheme to pay doctors to prescribe Botox, the wrinkle treatment, offering payments up to $490; and the China arm of a global trial caused a nine-month delay in the approval process of Eliquis because of errors in trial administration. More details….
Stock Symbols: (NSDQ: SCLN) (OTCQB: SNGX) (OTCQB: DMPI) (SHA: 600252) (NYSE: GSK)
Help employers find you! Check out all the jobs and post your resume.
